LAVIAT 25 MG CAP. 1X10 CAP.

About

LAVIAT is an oral tyrosine kinase inhibitor (TKI) that targets and inhibits the epidermal growth factor receptor (EGFR, also known as ErbB1) and human epidermal growth factor receptor 2 (HER2, also known as ErbB2) pathways. These receptors are crucial for cell growth, proliferation, and survival, and their overexpression or activation is frequently observed in various cancers, particularly breast cancer. By blocking the intracellular phosphorylation of these receptors, LAVIAT disrupts the downstream signaling cascades that promote tumor cell growth and division. This dual inhibition strategy makes it effective in treating cancers that are driven by these specific molecular pathways.

Its mechanism of action helps to slow or stop the growth of cancer cells and can lead to tumor regression. LAVIAT is typically used in combination with other chemotherapy agents or hormonal therapies to enhance its efficacy. It represents a targeted therapy approach, offering a valuable treatment option for patients with specific types of advanced or metastatic breast cancer, especially those whose tumors overexpress HER2 and have progressed on prior therapies. The oral capsule formulation provides convenience for long-term management.

Uses

• Treatment of advanced or metastatic breast cancer with HER2 overexpression.
• Used in combination with capecitabine for patients who have received prior therapy.
• Used in combination with letrozole for postmenopausal women with hormone receptor-positive, HER2-positive metastatic breast cancer.
• Treatment of specific solid tumors with EGFR/HER2 mutations.

Directions For Use

Take orally, usually once daily, with or without food as directed by your doctor. Do not crush or chew capsules.

Benefits

• Targets specific cancer growth pathways (EGFR/HER2).
• Effective in HER2-positive metastatic breast cancer.
• Can be used in combination with other therapies.
• Oral administration offers convenience.
• May improve progression-free survival.
• Provides an option for patients with refractory disease.

Side Effects

• Diarrhea
• Rash
• Nausea and vomiting
• Fatigue
• Palmar-plantar erythrodysesthesia (hand-foot syndrome)
• Stomatitis
• Anorexia
• Dry skin
• Hepatotoxicity (liver damage)
• Cardiac dysfunction (e.g., decreased LVEF)
• Pneumonitis
• QT prolongation

Safety Measures

• Alcohol - Avoid alcohol as it may increase the risk of liver toxicity or exacerbate gastrointestinal side effects.
• Pregnancy - Contraindicated in pregnancy due to potential for fetal harm. Effective contraception is required.
• Breastfeeding - Breastfeeding is not recommended during treatment and for a period after the last dose due to potential harm to the infant.
• Liver - Use with caution in patients with hepatic impairment; dose adjustments are necessary. Monitor liver function closely.
• Kidney - No specific dose adjustment required for mild to moderate renal impairment. Use with caution in severe impairment.
• Lung - Monitor for signs of interstitial lung disease or pneumonitis, especially in patients with pre-existing lung conditions.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.